State Street’s Protalix BioTherapeutics PLX Stock Holding History

State Street’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.11M	Buy	972,815 +387,554	+66%	+$962K	﹤0.01%	3283
2025 Q4	$1.05M	Buy	585,261 +86,714	+17%	+$177K	﹤0.01%	3519
2025 Q3	$1.11M	Buy	498,547 +54,308	+12%	+$88.4K	﹤0.01%	3489
2025 Q2	$657K	Buy	+444,239	New	+$909K	﹤0.01%	3567
2024 Q2	–	Sell	-826,581	Closed	-$1.04M	–	4386
2024 Q1	$1.04M	Hold	826,581	–	–	﹤0.01%	3460
2023 Q4	$1.47M	Buy	826,581 +66,607	+9%	+$104K	﹤0.01%	3395
2023 Q3	$1.26M	Buy	759,974 +28,737	+4%	+$51.6K	﹤0.01%	3465
2023 Q2	$1.46M	Buy	+731,237	New	+$1.74M	﹤0.01%	3507

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's PLX Position: Q1 2026 in Review

State Street increased its Protalix BioTherapeutics (PLX) stake by 66% in Q1 2026, buying an estimated $962K and bringing the position to 972,815 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3283.

State Street first reported a position in PLX in Q2 2023 and has held it in 8 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

State Street held 972,815 shares of Protalix BioTherapeutics worth $2.11M as of Q1 2026.
State Street bought 387,554 Protalix BioTherapeutics shares in Q1 2026, an estimated $962K.
Protalix BioTherapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3283 holding.
State Street first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 8 quarters since.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.